Interaction of 2,3-benzodiazepines with peripheral benzodiazepine receptors

Ágnes Kenessey, L. Gráf, Piroska Páldi-Haris, Tibor Láng

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

2,3-Benzodiazepines (BZs), such as tofizopam (TP) and GYKI-51 189 have anxiolytic potency accompanied by moderate sedative action, but no anticonvulsant and muscle relaxant activities. These compounds show relatively low affinity to the peripheral benzodiazepine (PBZ) receptors, nevertheless, they decrease the binding of (3H)Ro5-4864 to its receptors in heart, kidney and brain membranes. This diminution in the binding is due to a decrease in the affinity for the ligand (Kd) without any charge in the maximal number of binding sites (Bmax). This interaction of 2,3-BZs with PBZ binding sites may explain their pharmacological profile.

Original languageEnglish
Pages (from-to)1-14
Number of pages14
JournalPharmacological Research Communications
Volume19
Issue number1
DOIs
Publication statusPublished - 1987

Fingerprint

GABA-A Receptors
Benzodiazepines
Binding Sites
Anti-Anxiety Agents
Hypnotics and Sedatives
Anticonvulsants
Pharmacology
Ligands
Kidney
Muscles
Membranes
Brain

ASJC Scopus subject areas

  • Pharmacology

Cite this

Interaction of 2,3-benzodiazepines with peripheral benzodiazepine receptors. / Kenessey, Ágnes; Gráf, L.; Páldi-Haris, Piroska; Láng, Tibor.

In: Pharmacological Research Communications, Vol. 19, No. 1, 1987, p. 1-14.

Research output: Contribution to journalArticle

Kenessey, Ágnes ; Gráf, L. ; Páldi-Haris, Piroska ; Láng, Tibor. / Interaction of 2,3-benzodiazepines with peripheral benzodiazepine receptors. In: Pharmacological Research Communications. 1987 ; Vol. 19, No. 1. pp. 1-14.
@article{16c043a0a32141a4a494fd33e4b9d683,
title = "Interaction of 2,3-benzodiazepines with peripheral benzodiazepine receptors",
abstract = "2,3-Benzodiazepines (BZs), such as tofizopam (TP) and GYKI-51 189 have anxiolytic potency accompanied by moderate sedative action, but no anticonvulsant and muscle relaxant activities. These compounds show relatively low affinity to the peripheral benzodiazepine (PBZ) receptors, nevertheless, they decrease the binding of (3H)Ro5-4864 to its receptors in heart, kidney and brain membranes. This diminution in the binding is due to a decrease in the affinity for the ligand (Kd) without any charge in the maximal number of binding sites (Bmax). This interaction of 2,3-BZs with PBZ binding sites may explain their pharmacological profile.",
author = "{\'A}gnes Kenessey and L. Gr{\'a}f and Piroska P{\'a}ldi-Haris and Tibor L{\'a}ng",
year = "1987",
doi = "10.1016/0031-6989(87)90028-2",
language = "English",
volume = "19",
pages = "1--14",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Interaction of 2,3-benzodiazepines with peripheral benzodiazepine receptors

AU - Kenessey, Ágnes

AU - Gráf, L.

AU - Páldi-Haris, Piroska

AU - Láng, Tibor

PY - 1987

Y1 - 1987

N2 - 2,3-Benzodiazepines (BZs), such as tofizopam (TP) and GYKI-51 189 have anxiolytic potency accompanied by moderate sedative action, but no anticonvulsant and muscle relaxant activities. These compounds show relatively low affinity to the peripheral benzodiazepine (PBZ) receptors, nevertheless, they decrease the binding of (3H)Ro5-4864 to its receptors in heart, kidney and brain membranes. This diminution in the binding is due to a decrease in the affinity for the ligand (Kd) without any charge in the maximal number of binding sites (Bmax). This interaction of 2,3-BZs with PBZ binding sites may explain their pharmacological profile.

AB - 2,3-Benzodiazepines (BZs), such as tofizopam (TP) and GYKI-51 189 have anxiolytic potency accompanied by moderate sedative action, but no anticonvulsant and muscle relaxant activities. These compounds show relatively low affinity to the peripheral benzodiazepine (PBZ) receptors, nevertheless, they decrease the binding of (3H)Ro5-4864 to its receptors in heart, kidney and brain membranes. This diminution in the binding is due to a decrease in the affinity for the ligand (Kd) without any charge in the maximal number of binding sites (Bmax). This interaction of 2,3-BZs with PBZ binding sites may explain their pharmacological profile.

UR - http://www.scopus.com/inward/record.url?scp=0023109922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023109922&partnerID=8YFLogxK

U2 - 10.1016/0031-6989(87)90028-2

DO - 10.1016/0031-6989(87)90028-2

M3 - Article

VL - 19

SP - 1

EP - 14

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 1

ER -